Client News/Details

Snell & Wilmer Advises Bio-Systems Company TARGAN as it Secures $35 Million in Series C Financing

June 1, 2022

SAN DIEGO – Snell & Wilmer advised TARGAN, Inc. (TARGAN), a bio-systems company focused on improving animal health and productivity in the poultry industry, as it secured $35 million in Series C financing co-led by Mountain Group Partners and NovaQuest Capital Management. The Series C investment is projected to allow TARGAN to accelerate the commercialization of its automated and individualized poultry vaccination and gender identification systems.

“From its conception, TARGAN’s purpose has been to address the growing global demand for a healthier, more sustainable food supply through the development and application of novel technologies,” said Ramin Karimpour, founder and CEO of TARGAN in a recent press release. “We are most delighted that our great progress has led to NovaQuest joining our existing investors in this series. With this round, we will launch our targeted, individual vaccination and gender sorting technologies for poultry. Precise bird vaccination enables poultry producers to protect each bird from harmful diseases and significantly reduces the reliance on chemicals, therapeutics, and antibiotics. Additionally, automated gender identification will allow for separate sex rearing that reduces feed cost and waste while optimizing bird nutrition.”

Bardia Moayedi served as special counsel to TARGAN in the Series C financing. 

Snell & Wilmer's corporate and securities attorneys have served as counsel to a substantial number of clients ranging from Fortune 100 companies to smaller emerging businesses. Our attorneys have provided sophisticated legal representation to biotech companies, health care and financial institutions, public utilities, homebuilders, transportation companies, restaurant and hospitality providers, athletic complexes, fitness facilities and many other types of businesses. Snell & Wilmer’s venture capital and private equity practice covers multiple aspects of the transactional arena involving public and private companies, including the structuring and execution of majority buyouts and minority investments, acquisitions (including buy- and sell-side deals, as well as negotiated and auction deals), financings (including 144A transactions and PIPEs), going-private transactions, and spin-off transactions. Our venture capital and private equity attorneys advise both domestic and international funds, including venture capital, private equity, hedge, mezzanine, real estate opportunity, fund-of-funds, exchange, and other private investment funds.